guest ::
| Home > Publications database > Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework > print |
| Home > Publications database > Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework > print |
| 001 | 904295 | ||
| 005 | 20230123101901.0 | ||
| 024 | 7 | _ | |a 10.1007/s00259-020-05156-4 |2 doi |
| 024 | 7 | _ | |a 0340-6997 |2 ISSN |
| 024 | 7 | _ | |a 1432-105X |2 ISSN |
| 024 | 7 | _ | |a 1619-7070 |2 ISSN |
| 024 | 7 | _ | |a 1619-7089 |2 ISSN |
| 024 | 7 | _ | |a 2128/32286 |2 Handle |
| 024 | 7 | _ | |a 33590274 |2 pmid |
| 024 | 7 | _ | |a WOS:000618156900001 |2 WOS |
| 037 | _ | _ | |a FZJ-2021-05865 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Bischof, Gerard Nisal |0 P:(DE-Juel1)166265 |b 0 |e Corresponding author |
| 245 | _ | _ | |a Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework |
| 260 | _ | _ | |a Heidelberg [u.a.] |c 2021 |b Springer-Verl. |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1667393832_10164 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a AbstractPurpose: In 2017, the Geneva Alzheimer's disease (AD) strategic biomarker roadmap initiative proposed a framework of the systematic validation AD biomarkers to harmonize and accelerate their development and implementation in clinical practice. Here, we use this framework to examine the translatability of the second-generation tau PET tracers into the clinical context.Methods: All available literature was systematically searched based on a set of search terms that related independently to analytic validity (phases 1-2), clinical validity (phase 3-4), and clinical utility (phase 5). The progress on each of the phases was determined based on scientific criteria applied for each phase and coded as fully, partially, preliminary achieved or not achieved at all.Results: The validation of the second-generation tau PET tracers has successfully passed the analytical phase 1 of the strategic biomarker roadmap. Assay definition studies showed evidence on the superiority over first-generation tau PET tracers in terms of off-target binding. Studies have partially achieved the primary aim of the analytical validity stage (phase 2), and preliminary evidence has been provided for the assessment of covariates on PET signal retention. Studies investigating of the clinical validity in phases 3, 4, and 5 are still underway.Conclusion: The current literature provides overall preliminary evidence on the establishment of the second-generation tau PET tracers into the clinical context, thereby successfully addressing some methodological issues from the tau PET tracer of the first generation. Nevertheless, bigger cohort studies, longitudinal follow-up, and examination of diverse disease population are still needed to gauge their clinical validity.Keywords: Alzheimer’s disease; Biomarker-based diagnosis; Second-generation tau PET tracers; Strategic roadmap. |
| 536 | _ | _ | |a 5253 - Neuroimaging (POF4-525) |0 G:(DE-HGF)POF4-5253 |c POF4-525 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de |
| 700 | 1 | _ | |a Dodich, Alessandra |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Boccardi, Marina |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a van Eimeren, Thilo |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Festari, Cristina |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Barthel, Henryk |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Hansson, Oskar |0 P:(DE-HGF)0 |b 6 |
| 700 | 1 | _ | |a Nordberg, Agneta |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Ossenkoppele, Rik |0 P:(DE-HGF)0 |b 8 |
| 700 | 1 | _ | |a Sabri, Osama |0 P:(DE-HGF)0 |b 9 |
| 700 | 1 | _ | |a Giovanni, B Frisoni G |0 P:(DE-HGF)0 |b 10 |
| 700 | 1 | _ | |a Garibotto, Valentina |0 P:(DE-HGF)0 |b 11 |
| 700 | 1 | _ | |a Drzezga, Alexander |0 P:(DE-Juel1)177611 |b 12 |
| 773 | _ | _ | |a 10.1007/s00259-020-05156-4 |g Vol. 48, no. 7, p. 2110 - 2120 |0 PERI:(DE-600)2098375-X |n 7 |p 2110 - 2120 |t European journal of nuclear medicine and molecular imaging |v 48 |y 2021 |x 0340-6997 |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/904295/files/s00259-020-05156-4.pdf |y OpenAccess |
| 909 | C | O | |o oai:juser.fz-juelich.de:904295 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany. gerard.bischof@uk-koeln.de |0 I:(DE-HGF)0 |b 0 |6 P:(DE-Juel1)166265 |
| 910 | 1 | _ | |a NIMTlab, Neuroimaging and Innovative Molecular Tracers Laboratory, University of Geneva, Geneva, Switzerland |0 I:(DE-HGF)0 |b 1 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Center for Neurocognitive Rehabilitation (CeRiN), CIMeC, University of Trento, Trento, Italy |0 I:(DE-HGF)0 |b 1 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a German Center for Neurodegenerative Disorders (DZNE), Rostock/Greifswald, Rostock, Germany |0 I:(DE-HGF)0 |b 2 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a German Center for Neurodegenerative Disorders (DZNE), Bonn/Cologne, Germany |0 I:(DE-HGF)0 |b 2 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a German Center for Neurodegenerative Disorders (DZNE), Bonn/Cologne, Germany |0 I:(DE-HGF)0 |b 3 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a German Center for Neurodegenerative Disorders (DZNE), Rostock/Greifswald, Rostock, Germany |0 I:(DE-HGF)0 |b 3 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany |0 I:(DE-HGF)0 |b 3 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a LANE - Laboratory of Alzheimer's Neuroimaging and Epidemiology, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy |0 I:(DE-HGF)0 |b 4 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany |0 I:(DE-HGF)0 |b 5 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Memory Clinic, Skåne University Hopsital, Malmö, Sweden |0 I:(DE-HGF)0 |b 6 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden |0 I:(DE-HGF)0 |b 6 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden |0 I:(DE-HGF)0 |b 7 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden |0 I:(DE-HGF)0 |b 8 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, Netherlands |0 I:(DE-HGF)0 |b 8 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany |0 I:(DE-HGF)0 |b 9 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a NIMTlab, Neuroimaging and Innovative Molecular Tracers Laboratory, University of Geneva, Geneva, Switzerland |0 I:(DE-HGF)0 |b 10 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Memory Center - Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva, Switzerland |0 I:(DE-HGF)0 |b 10 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a NIMTlab, Neuroimaging and Innovative Molecular Tracers Laboratory, University of Geneva, Geneva, Switzerland |0 I:(DE-HGF)0 |b 11 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Nuclear Medicine and Molecular Imaging Division, Diagnostic Department, Geneva University Hospitals, Genève, Switzerland |0 I:(DE-HGF)0 |b 11 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 12 |6 P:(DE-Juel1)177611 |
| 910 | 1 | _ | |a German Center for Neurodegenerative Disorders (DZNE), Rostock/Greifswald, Rostock, Germany |0 I:(DE-HGF)0 |b 12 |6 P:(DE-Juel1)177611 |
| 910 | 1 | _ | |a German Center for Neurodegenerative Disorders (DZNE), Bonn/Cologne, Germany |0 I:(DE-HGF)0 |b 12 |6 P:(DE-Juel1)177611 |
| 910 | 1 | _ | |a Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany |0 I:(DE-HGF)0 |b 12 |6 P:(DE-Juel1)177611 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-525 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Decoding Brain Organization and Dysfunction |9 G:(DE-HGF)POF4-5253 |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2021-02-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2021-02-02 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-02-02 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2021-02-02 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b EUR J NUCL MED MOL I : 2019 |d 2021-02-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2021-02-02 |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2021-02-02 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2021-02-02 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2021-02-02 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b EUR J NUCL MED MOL I : 2019 |d 2021-02-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-02-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2021-02-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2021-02-02 |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-2-20090406 |k INM-2 |l Molekulare Organisation des Gehirns |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)INM-2-20090406 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|